Baxter International Inc. Sadia Ritu
Global Diversified
History Founded by Dr. Don Baxter in 1931 First manufacture of commercially prepared IV solutions Bought out by Dr. Ralph Falk in 1935 and development of a research division Headquarter in Deerfield Illinois 1939 ‘Transfuso-Vac container’, the first sterile, vacuum- type blood collection and storage unit.
2011 Sales by Business
BioScience Recombinant (36%) Antibody Therapy (26%), Plasma Proteins (23%), Regenerative Medicine (11%) others (4%).
Medical Products Renal (32%) Global Injectable (26%), IV Therapy (24%), Infusion System (10%), Anesthesia (7%) Others (1%)
Sales and distribution
Supplier Relations Operations
Research and Development
2011 Sales by Region
Regional Growth: North America Europe, Middle East & Africa Latin America & Canada Asia Pacific
Acquisitions
Industry Medical Instruments and Supplies Industry billion -5.8% growth rate Healthcare sector In the U.S., people over the age of 65 is expected to be about 49.7 million over the next 5 years.
The economic effect Healthcare Reform Tax increase in 2013 Management & Employees Baxter’s management guidance
Svigals Portfolio: 45 shares currently ($50.13/ share) 31.28% unrealized gain Tall Firs Portfolio: 340 BAX shares purchased in ($27-28/ share) about 120% unrealized gain Portfolio History
Downside FDA and EMA risk of approval. Suppliers Upcoming tax increase of 2013 on medical device companies. Product quality or patient safety issues, leading to product recalls or withdrawals. Fluctuations in foreign exchange and interest rates.
Recent Happenings: Baxter Said to Near Deal to Buy Gambro for $4 Billion -Nov 24, 2012 Baxter Declares Quarterly Dividend –Nov 13, 2012
Dividends
FMS 30% COV 22% MDT 5% BDX 43%
Discounted Cash Flow Analysis -Beta
-Revenue Model -Cost Of Goods Sold -SG&A -Cap Ex -Tax Rate
Weights: DCF-70% Comp-30% Implied Price: $70.94
Questions?
Hold Recommendation Long term growth 80 years long Healthcare leader Global expansions Diverse